PES1, a BRCT domain-containing protein, has been shown to play a role in modulating the balance and ratio between ERα and ERβ protein, which is involved in the occurrence and development of breast and ovarian cancer. However, its role in connection with the balance and ratio between ERα and ERβ protein in papillary thyroid cancer (PTC) remains unclear. Here, we found that ERα and ERβ were co-expressed in human PTC tissues and cells. ERα promoted and ERβ inhibited the proliferation, invasion and migration of PTC cells. PES1 modulated the balance between ERα and ERβ by elevating the ERα protein level and simultaneously reducing the ERβ protein level, then upregulating the ERα/ eRβ protein ratio and promoting the proliferation, invasion and migration of PTC cells. In PTC tissues, PES1 protein level was positively correlated with the ERα protein level and negatively correlated with the ERβ protein level. The PES1 and ERα protein levels were gradually increased and the ERβ protein level was decreased by degree in the occurrence and development of PTC. Increased PES1 and ERα protein levels and decreased ERβ protein level were correlated with the aggressive behaviors of PTC patients such as large tumor size, extrathyroidal extension (ETE), lymph node metastasis (LNM), high BRAFV600E expression and high TNM stage. It is suggested that PES1 promotes the occurrence and development of PTC by elevating the ERα protein level and reducing the ERβ protein level, and then upregulating the ERα/eRβ protein ratio.
. The elevated risk was also reported in women who used estrogen for gynecological problems and in women who used postmenopausal hormone replacement therapy or oral contraception [3] [4] [5] . It is suggested that estrogen may be involved in the occurrence and development of PTC, as has been shown in breast, endometrial and ovarian cancer 6 . Estrogen exerts its physiological and pathophysiological actions largely through two estrogen receptors, ERα and ERβ, which belong to the steroid hormone receptor family 7, 8 . ERα and ERβ are architecturally similar with three functional domains: N-terminal domain (NTD), DNA binding domain (DBD) and ligand binding domain (LBD). The two ERs share 97% similarity in their DBD and 59% in LBD, whereas the NTD is merely 16% similar 9 . The differences in their structures suggest that ERα and ERβ may have different functions. It is well known that ERα expression is associated with aberrant proliferation and the development of malignancy, in contrast, ERβ has been shown to inhibit cell proliferation, migration and invasion 10, 11 . Although there is a controversy regarding the prognostic and predictive roles of ERβ expression, most of the studies that have analyzed a large number of samples have demonstrated a correlation of ERβ expression with a better clinical outcome in estrogen related cancer 12, 13 . Lots of studies have shown that ERα promotes cell proliferation, invasion and migration and has been shown to have tumor-promoting effects, whereas ERβ may play an inhibitory role against the ERα-mediated tumor-promoting effects, especially when co-expressed with ERα [14] [15] [16] . The ERα/ERβ protein ratio would be critical in defining the overall response. Therefore, the imbalance between ERα and ERβ protein levels and the elevated ERα/ERβ protein ratio may be implicated in the occurrence and development of tumor in estrogen responsive organ 17, 18 . Previous studies have shown that like the typical estrogen responsive organ such as breast, uterus and ovary, both ERα and ERβ are co-expressed in the normal and tumor tissues of the thyroid 19, 20 . Moreover, like in breast, endometrial and ovarian cancer, ERα protein is increased, ERβ protein is decreased and finally the ERα/ERβ protein ratio is upregulated, which is involved in the occurrence and development of PTC [21] [22] [23] [24] . However, how the protein levels of ERα and ERβ are modulated and how the ERα/ERβ protein ratio is upregulated in PTC remain unclear.
PES1, a breast cancer-associated gene 1 (BRCA1) C-terminal (BRCT) domain-containing protein, has been shown to play important roles in normal embryonic development, ribosome biogenesis, DNA replication, chromosomal stability and cell cycle progression [25] [26] [27] [28] . Previous studies have demonstrated that PES1 is widely expressed in developing tissues, but is not observed in any adult tissues except for the ovary 26, 27 . However, the subsequent studies have revealed that PES1 is over-expressed in some cancers such as stomach cancer 29 , prostatic cancer 30, 31 , breast cancer 32, 33 , head and neck squamous cell cancer 34 , colon cancer 35 , malignant astrocytomas and glioblastomas 36, 37 and ovarian cancer 38 . High PES1 expression is associated with the worse overall and relapse-free survival of patients with malignant tumor. The increased expression of PES1 transforms both mouse and human fibroblasts 39 , while the repression of PES1 inhibits the proliferation and tumorigenicity of breast cancer cells 32, 33 . These data suggest that PES1 promotes the proliferation and malignant transformation of cells and may contribute to the occurrence and development of tumor.
Recently, Cheng et al. 33 and Li et al. 38 reported a novel function of PES1 that modulates the balance between ERα and ERβ protein levels through the ubiquitin-proteasome pathway, which contributes to the growth of breast and ovarian cancer cells. However, its role in connection with the balance between ERα and ERβ protein levels and the ERα/ERβ protein ratio in PTC has not been studied yet. Here, we examined PES1 protein level in human PTC tissues and cells and assessed the correlations of PES1 protein level with ERα and ERβ protein levels, with various clinicopathological features of PTC patients and with the ERα/ERβ protein ratio and the proliferation, invasion and migration of PTC cells.
Results

PES1
and ERα protein levels are significantly upregulated and ERβ protein level is significantly downregulated in PTC tissues. PES1, ERα and ERβ protein levels in PTC and normal thyroid tissues were examined using immunohistochemical (IHC) staining and the examples of IHC staining for the three molecules were shown in Fig. 1A -C is an example of normal thyroid tissues showing almost no follicular cells with staining for PES1 (A) and a few of follicular cells with weak staining for ERα (B), however, a lot of follicular cells with strong staining for ERβ (C). D-F is an example of PTC tissues with small tumor size, low BRAFV600E expression and TNM stage I and without ETE and LNM, showing quite a few of tumor cells with moderate staining for PES1 (D), ERα (E) and ERβ (F). G-I is an example of PTC tissues with large tumor size, ETE, LNM, high BRAFV600E expression and TNM stage IV, showing a lot of tumor cells with strong staining for PES1 (G) and ERα (H), however, a few of tumor cells with weak staining for ERβ (I). It was indicated that PES1 and ERα protein levels are PES1 protein level and ERα/eRβ protein ratio are upregulated in human PTC cells. To examine the PES1 protein level in human PTC and normal thyroid cells, we preformed Western blotting using human PTC-derived BCPAP and K1 cells with BRAFV600E mutation and normal thyroid-derived Nthy-ori3-1 cells without BRAFV600E mutation 40 . As shown in Fig. 2A ,B, the PES1 protein level was much higher in BCPAP and K1 cells than that in Nthy-ori3-1 cells. To quantify the ERα/ERβ protein ratio in BCPAP, K1 and Nthy-ori3-1
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Discussion
Studies have shown that estrogen may be involved in the occurrence and development of PTC [1] [2] [3] [4] [5] , as has been shown in breast, endometrial and ovarian cancer 6 . Estrogen exerts its effects mainly via ERα and ERβ 7, 8 . ERα and ERβ are often co-expressed and contribute to the physiological and pathophysiological responses of estrogen 42, 43 . In this study, we detected ERα and ERβ protein levels in PTC tissues and cells using IHC staining and Western blotting, respectively. Compared with normal thyroid tissues and cells, the ERα protein level was upregulated and the ERβ protein level was downregulated in PTC tissues and cells. PTC tissues had higher rates of high ERα and low ERβ protein expression. PTC cells had more than two times higher protein level of ERα than that of ERβ. This result is in line with the previous data showing that ERα and ERβ are co-expressed in normal and tumor tissues of the thyroid 20, 21 , compared with normal thyroid tissues, the level of ERα is relatively higher than that of ERβ in PTC tissues [21] [22] [23] [24] . Although ERα and ERβ are architecturally similar with three functional domains of N-terminal domain (NTD), DNA binding domain (DBD) and ligand binding domain (LBD), there are obvious differences in their structures of NTD and LBD. The differences in their structures suggest that ERα and ERβ may have different functions 9 . Cell-based assays have shown that ERβ is generally less active than ERα and may influence ERα activity. Despite a small number of data associating ERβ with pro-growth and pro-survival when present alone in ERα-negative estrogen related cancer tissues and cells, a large number of data both in vitro and in vivo support that ERβ acts as an anti-proliferative and pro-apoptotic factor, especially when co-expressed with ERα 44, 45 . Most studies have revealed that ERα promotes cell proliferation, invasion and migration and has been shown to have tumor-promoting effects, whereas ERβ, when co-expressed with ERα, may play an inhibitory role against the ERα-mediated tumor-promoting effects [14] [15] [16] . Thus, the complement of ER isoform could influence the biological responses and the balance and ratio between ERα and ERβ protein levels would be critical in defining the overall response [14] [15] [16] [17] [18] . In this study, we showed that compared with normal thyroid tissues, the ERα protein level was upregulated and the ERβ protein level was downregulated in PTC tissues. The ERα protein level was positively correlated with the aggressive behaviors of PTC patients, conversely, the ERβ protein level was negatively correlated with the aggressive behaviors of PTC patients. PTC patients with large tumor size, ETE, LNM, high BRAFV600E expression and high TNM stage (III-IV) had higher rates of high ERα and low ERβ protein expression. Moreover, cell-based assays showed that the ERα/ERβ protein ratio was greater than one (>1) in human PTC-derived BCPAP and K1 cells with the BRAFV600E mutation, conversely, smaller than one (<1) in normal thyroid-derived Nthy-ori3-1 cells without the BRAFV600E mutation. ERα promoted and ERβ inhibited the proliferation, invasion and migration of these PTC cells and normal thyroid cells. Interestingly, E2 increased the proliferation, invasion and migration of human PTC cells with an ERα/ERβ protein ratio of >1, however, decreased the proliferation, invasion and migration of normal thyroid cells with an ERα/ERβ protein ratio of <1. It was indicated that the ERα/ERβ protein ratio is crucial to the effects of E2 on the proliferation, invasion and migration of these thyroid cells.
PES1, a BRCT domain-containing protein, is essential for ribosome biogenesis, nucleologenesis and cell growth, which are all important components that determine the cell proliferation rate 25, 28 . The increased expression of PES1 is involved in the proliferation and malignant conversion of cells and may contribute to the occurrence and development of some human cancers such as prostate, head and neck, stomach, colon, breast and ovarian cancer [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] . Recently, Cheng et al. 33 and Li et al. 38 reported a novel function of PES1 that regulates the balance between ERα and ERβ protein levels. They found that PES1 enhances the stability of ERα while simultaneously targeting ERβ for proteasome degradation, thereby increasing the protein level of ERα and decreasing that of ERβ, which contributes to the occurrence and development of breast cancer and ovarian cancer. As some ERs regulators have been found to have tissue specificity that modulate their activities 46, 47 , in this study, we examined PES1 protein level in PTC tissues and cells and assessed the correlations of its protein level with the ERα and ERβ protein levels and with the occurrence and development of PTC. We found that PES1 protein level was positively correlated with ERα protein level and negatively correlated with ERβ protein level in human PTC tissues and cells. Compared with normal thyroid tissues, PES1 protein level was significantly increased in PTC tissues and was associated with the aggressive behaviors of PTC patients. PTC patients with large tumor size, ETE, LNM, high BRAFV600E expression and high TNM stage (III-IV) had higher rates of high PES1 and ERα protein levels and low ERβ protein level. Increased PES1 and ERα protein levels and decreased ERβ protein level were associated with the occurrence and development of PTC. Cell-based assays showed that PES1 elevated ERα protein level and simultaneously reduced ERβ protein level and resulted in an upregulated ERα/ERβ protein ratio, and then promoted the proliferation, invasion and migration of human PTC cells.
In summary, ERα and ERβ were co-expressed in human PTC tissues and cells. ERα promoted and ERβ inhibited the proliferation, invasion and migration of PTC cells. PES1 modulated the balance between ERα and ERβ by elevating the ERα protein level and simultaneously reducing the ERβ protein level, then upregulated the ERα/ ERβ ratio and promoted the proliferation, invasion and migration of PTC cells. In PTC tissues, PES1 protein level was positively correlated with ERα protein level and negatively correlated with ERβ protein level. PES1 and ERα protein levels were gradually increased and ERβ protein level was decreased by degree in the occurrence and development of PTC. Increased PES1 and ERα protein levels and decreased ERβ protein level were correlated with the aggressive behaviors of PTC patients such as large tumor size, ETE, LNM, high BRAFV600E expression and high TNM stage. It was suggested that PES1 promotes the occurrence and development of PTC by elevating the ERα protein level and reducing the ERβ protein level, and then upregulating the ERα/ERβ protein ratio.
Materials and Methods
Case selection and tissue samples. Tumor tissue samples were obtained from 200 PTC patients who underwent initial thyroidectomy in the Department of Surgery, the First Affiliated Hospital, Chongqing Medical University, between January 2015 and January 2017. At initial thyroidectomy, cervical lymph node dissection (CLND) was performed, tumor size was assessed, histologic subtype was defined and extrathyroidal extension (ETE) and BRAFV600E mutation were evaluated. Of the 200 cases, 142 were classic PTC, 21 follicular variant of PTC, 24 tall cell variant of PTC and 13 oncocytic variant of PTC. There were 39 patients with ETE, 90 patients with lymph node metastasis (LNM), 133 patients with high BRAFV600E expression, 62 patients with tumor size of ≤2 cm, 71 patients with tumor size of >2 and ≤4 cm and 67 patients with tumor size of >4 cm. Of this patient cohort, 46 were men and 154 women; 24 patients were aged <45 years and 176 were aged ≥45 years. According to the seventh edition of thyroid cancer tumor-node-metastasis (TNM) staging system by American Joint Committee on Cancer, 50 patients were stage I, 50 patients stage II, 50 patients stage III and 50 patients stage IV. For statistical analysis, stage I and II were combined into low TNM stage (I-II) and stage III and IV were combined into high TNM stage (III-IV). Besides, 200 normal thyroid tissues were taken from the contralateral lobes of PTC tissues. The study protocol was approved by the Ethics Committee of Chongqing Medical University and informed consent was obtained from all of the patients.
Tissue microarray and IHC staining. Tissue microarray construction and IHC staining were performed as described previously 48 . Rabbit polyclonal anti-PES1 (ab72539), mouse monoclonal anti-ERα (ab1104) and Cell culture and treatment. Human PTC-derived BCPAP and K1 cells with BRAFV600E mutation and normal thyroid-derived Nthy-ori3-1 cells without BRAFV600E mutation 40 were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and maintained in RPMI-1640 medium supplemented with 10% charcoal-stripped fetal bovine serum (FBS) (GBICO Co., Ltd., Grand Island, NY, USA). The cells were incubated in phenol-red free and serum free medium for 48 h before stimulation with 17β-estradiol (E2), propyl-pyrazole-triol (PPT) and diarylpropionitrile (DPN) (Sigma, St Louis, MO, USA). Cell treatments were performed as indicated in the respective figure legends.
Construction of shRNA expression vectors for PES1, ERα and ERβ. For a vector-based RNA interference (RNAi) approach, short hairpin RNA (shRNA) was cloned into the BamHI-HindIII sites of the pRNAT-U6.1/neo vector (GenScript Corp. Piscataway, NJ, USA). RNAi target sequences were selected from the human PES1, ERα and ERβ sequences (GenBank accession NM_001282328.1 for PES1, NM_001122741.1 for ERα and NM_001291723.1 for ERβ). The candidate target sequences were analyzed by BLAST search to ensure that the knockdown would be unique to PES1, ERα and ERβ. The specific shRNA sequences were 5 ′-G GA TT C CC GG CC AG AA GA TC AT GT TT GG CA A TT CA AG AG A TT GC CA AA CA TG ATCTT CTGGTTTTTGAAGCTT-3′ for PES1, 5′-GGATTCCCGGCTACAGGCCAAATTCAGATAA TTCAAGAGATT ATCTGAATTTGGCCTGTAGTTTTTGAAGCTT-3′ for ERα and 5′-GGATTC CCGGGCGAGTAACAAG GGCATGGAATTCAAGAGATTCCATGCCCTTGTTACTCGCTTTTTGAAGCTT-3′ for ERβ. A nonsilencing RNAi control vector comprising a scrambled shRNA sequence was generated with the following oligonucleotide 5′-GGATTCCCGGCCTAAGGTTAAGTCGCCC TCGTTCAAGAGACGAGGGCGACTTAACCTTAGG TTTTTGAAGCTT-3′. The underlined, boldface and italic letters denote the hairpin loop, terminal signal and target sites of BamHI and HindIII restriction enzymes, respectively. These shRNA sequences were digested with BamHI and HindIII restriction enzymes (Takara Biotechnology Co., Ltd., Dalian, China) and cloned into the pRNAT-U6.1/neo vector with T4 ligase (Takara). The resulting constructs were verified by direct sequencing (Sangon Biotech Co., Ltd., Shanghai, China).
Construction of PES1 expression vector.
Full-length PES1 cDNA was amplified by PCR using human universal QUICK clone cDNA (Clonetech Laboratories Inc., Mountain View, CA, USA) as a PCR template and specific primers based on PES1 cDNA sequence (GenBank Accession: NC_000022.11). The specific primers were as follows: forward 5′-ATAATTGGATTCGCCACCATGGGAGGCCTTGAGAAGA-3′ and reverse 5′-ATTATAAAGCTTCTCCGGCCTTGCCTTCTTGGCCTTC-3′. The underlined and italic letters denote the target sites of BamHI and HindIII restriction enzymes and the additional sequence, respectively. The PCR product containing the PES1 open-reading frame sequence was digested with BamHI and HindIII restriction enzymes (Takara) and cloned into the pcDNA3.1 expression vector (Invitrogen, Carlsbad, CA, USA) with T4 ligase (Takara). The resulting construct was verified by direct sequencing (Sangon Biotech Co., Ltd, Shanghai, China).
Transfection.
A single day prior to transfection, cells were seeded in 6-well culture plates at a density of 5.0 × 10 5 cells per well (2.0 ml/well). Transfection was performed using Lipofectamine 2000 reagent (Invitrogen) in accordance with the standard protocol of the manufacturer. In brief, transfection was initiated when the cells were 70-80% confluent. For each well, 5 μg of plasmid DNA was added into 250 μl of Opti-MEM (Invitrogen), 5 μl of lipofectamine 2000 into 250 μl of Opti-MEM, and then mixed plasmid DNA with Lipofectamine 2000. The mixture was added to cells in the 6-well culture plates, giving an end volume of 1 ml. The Opti-MEM medium containing complex was incubated for 8 h at 37 °C, then replaced with 2 ml of standard growth media and cultured for 48 h at 37 °C. Stable transfected cells were selected in the presence of 400 μg/ml of G418 (GIBCO) for 3 weeks with medium change on every 4th or 5th day.
Protein extraction and Western blotting. Cells were harvested and gently lysed for 30 min in 5 volumes of ice-cold RIPA buffer (Sigma) supplemented with Complete Protease Inhibitor Cocktail (Roche Diagnostics, Mannheim, Germany) at a ratio of 1000:1. Cell lysates were centrifuged at 10 000 × g for 10 min at 4 °C to obtain the supernatants. The protein content of cell lysates was quantified by the Bio-Rad Dc Protein Assay kit (Bio-Rad Laboratories, Hercules, CA, USA). Western blotting was performed as described previously. Briefly, 30 μg of total cell protein was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA, USA transferred membranes were probed with anti-PES1 (ab72539, Abcam), anti-ERα (ab1104, Abcam), anti-ERβ (ab1103, Abcam) and anti-β-actin (ab8227, Abcam) primary antibodies overnight at 4 °C and at 1:500 dilution. Subsequently, the membranes were washed and reacted with peroxidase-conjugated goat anti-mouse or goat anti-rabbit secondary antibodies (sc-2005 and sc-2004, Santa Cruz Biotechnology, CA, USA) for 1 h at room temperature and at 1:2000 dilution. The immunoreactive bands were visualized using an enhanced chemioluminescent ECL reagent (Amersham Biosciences, Piscataway, NJ, USA) and quantified using the TINA version 2.09 program package by normalizing to β-actin signal.
BrdU assay. Cells were seeded in 96-well culture plates at a density of 5 × 10 3 cells per well, incubated for 24 h, serum-deprived for 48 h and treated as indicated in the figure legends. Then a 5-bromo-2′-deoxyuridine (BrdU) incorporation colorimetric ELISA kit (Roche Diagnostics) was used to assay the cell proliferation in accordance with the standard protocol of the manufacturer.
Cell count assay. Cells were seeded in 6-well culture plates at a density of 2 × 10 5 cells per well, incubated for 24 h, serum-deprived for 48 h and treated as indicated in the figure legends. Then cells were harvested using Trypsin-EDTA, resuspended in the fresh medium and diluted in 0.4% trypan blue at a volume ratio of 1:1. The cell number was manually counted using a haemocytometer under microscope.
In vitro migration and invasion assays. In vitro migration and invasion assays were performed using transwell chambers (8-μm pore size, 24-well insert, Corning Inc., Corning, NY, USA) according to the manufacturer's instructions. Briefly, 3 × 10 4 serum-starved cells were resuspended and seeded in the upper chambers in phenol-red free and serum-free medium supplemented with or without E2, PPT or DPN. The lower chambers were filled with phenol-red free medium supplemented with 10% charcoal-stripped FBS as a chemoattractant. For the invasion assay, the inserts were pre-coated with extracellular matrix gel (BD Biosciences, Bedford, MA, USA). Following 72 h incubation, MTT solution (0.5 mg/mL) was added to the upper and lower chambers and incubated for another 4 h. After this, the cells in the upper membrane surface (residual cells) and the cells in the lower membrane surface (migrated or invaded cells) were scraped off with a cotton swab and dissolved in 400 μl of DMSO, respectively. Then 100 μl of the dissolved solution was taken and the absorbance was measured at 570 nm. Data were expressed as a percentage of migrated and invaded cells, i.e., A/(A + B) × 100, where A is the absorbance of the migrated or invaded cells and B the absorbance of the residual cells.
Statistics. Statistical analyses were performed using the SPSS version 18.0 (SPSS Inc., Chicago, IL, USA).
Data are presented as percentages and mean plus standard deviation, according to distribution. Significance was assessed using Chi-square, Spearman rank and Student's t-tests, as appropriate, to compare groups. A P-value of < 0.05 was considered to be statistically significant.
Statements for Materials and Methods. The study protocol was approved by the Ethics Committee of
Chongqing Medical University and informed consent was obtained from all of the patients. All experiments were performed in accordance with the relevant guidelines and regulations.
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